USA flag logo/image

An Official Website of the United States Government

Rapid antigen detection test for Dengue infection

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85322
Program Year/Program:
2007 / SBIR
Agency Tracking Number:
AI074172
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Rapid antigen detection test for Dengue infection
Agency: HHS
Contract: 1R43AI074172-01
Award Amount: $684,744.00
 

Abstract:

DESCRIPTION (provided by applicant): Dengue is a mosquito-transmitted acute viral disease of man caused by the Dengue virus, a member of the flaviviridae family. It is endemic in many parts of the world, particularly tropical and sub-tropical regions and q uite recently there have been outbreaks in Texas and Hawaii. It has been estimated that there are 100 million new case of Dengue infection per year, up to half a million of which progress to life-threatening Dengue Hemorrhagic Fever. Dengue is classified b y NIAID as a re-emerging pathogen and a Category A biodefense agent. Currently there is no vaccine and good management is critical for a successful resolution of the disease. A rapid, accurate diagnosis is the key to clinical decision making. Currently, di agnosis of infection is determined by either IgG or IgM ELISA or PCR. These tests have a number of drawbacks including cost, the time needed to carry them out, the requirement for expensive equipment and their sensitivity and specificity particularly in ac ute/early stage disease. Hence the need for improved Dengue testing is paramount. InBios International proposes to address this issue by developing a rapid, inexpensive, highly sensitive, point-of-care assay for the detection of viral antigens in the serum of infected individuals. In the pursuit of this objective, we will first identify type-specific Dengue antigens in the sera of patients at different stages of disease by using novel antibody microarrays constructed with a large, unique, panel of anti-deng ue Mabs. Once target antigens have been identified we will make lateral flow dipstick assays, or so-called rapid tests with the identified monoclonal antibodies and evaluate their performance in several Dengue-endemic regions (Taiwan, Puerto Rico). The s ensitivity of the antigen assay will be increased by the use of a specially constructed, high sensitivity hand held fluorescence reader. We intend that the fluorescence reader will be produced at very low cost. In the pursuit of these goals, InBios will dr aw on its considerable experience in flavivirus research (we have an FDA approved diagnostic for West Nile Virus) and furthermore has put together a world class team of biomedical scientists with peerless expertise in Dengue pathobiology, diagnostic develo pment and prototype instrument design. The aims of this application are to develop a specific antigen test for the early diagnosis of Dengue virus infections. This virus is endemic in many tropical and sub-tropical regions of the world and can be f atal. It is also listed as a bioterrorism agent. Early diagnosis could lead to improved treatment outcomes.

Principal Investigator:

Raymond Houghton
2063445821
RAYMOND@INBIOS.COM

Business Contact:

Raymond Houghton
wendy@inbios.com
Small Business Information at Submission:

INBIOS INTERNATIONAL, INC.
562 1ST AVE. SOUTH, SUITE 600 SEATTLE, WA 98104

EIN/Tax ID: 911791824
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No